Skip to content

Sparing the salivary glands to decrease the risk of xerostomia by intensity modulated radiotherapy in the treatment of head and neck cancer: a prospective clinical study

Sparing the salivary glands to decrease the risk of xerostomia by intensity modulated radiotherapy in the treatment of head and neck cancer: a prospective clinical study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONN-17010597
Enrollment
Unknown
Registered
2017-02-09
Start date
2017-03-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

head and neck cancer

Interventions

A:Protection of parotid gland and oral cavity
B:Protection of Submandibular gland and oral cavity
C:Protect oral cavity only
D:Protect both parotid gland, submandibular gland, and oral cavity

Sponsors

The General Hospital of People’s Liberation Army
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. the primary tumor is head and neck malignant tumor, including the parts of the mouth, throat, nasal cavity, sinuses, salivary gland; 2. the imaging examination ( MRI ) was enhanced, and the CT enhancement was used in Mr examination. The neck superficial linbajiecai ( super ) confirmed the scope and lymph node metastasis of primary disease; 3. definite pathological diagnosis and clinical stage; 4. life expectancy is more than 2 years; 5. cervical and supraclavicular lymph node metastasis is allowed; 6. no organ transfer; 7. allow induction chemotherapy, synchronous chemotherapy, consolidation of chemotherapy, targeted drug therapy and other treatment modalities; 8. no operation intervention was carried out; 9. the functional state score ( KPS ) score = 70, the physical status score ( ECOG ): 0-1socre; 10. Aged 18-65 years old; 11. complete medical records ( history, physical examination, related examination, treatment); 12. the feasible saliva flow rate and the table score of the regular dry mouth; 13. voluntary participation and written and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. other rheumatic immune system diseases such as Sjogren's syndrome; 2. salivary gland cyst operation or other physical therapy; 3. history of head and neck surgery trauma; 4. head and neckradiationthearpy; 5. refusal or unable to sign the written informed consent.

Design outcomes

Primary

MeasureTime frame
Velocity of saliva;xerostomia score;xerostomia score;OS;DFS;

Countries

China

Contacts

Public ContactMa Lin

The General Hospital of People’s Liberation Army

malinpharm@sina.com+86 13911197589

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 28, 2026